COPD and glycopyrronium responsiveness assessment: An appraisal.

Bhattacharyya, Parthasarathi; Saha, Dipanjan; Chatterjee, Moumita; Sengupta, Sayoni; Dey, Debkanya; Banerjee, Rajat

Bhattacharyya, Parthasarathi; Saha, Dipanjan; Chatterjee, Moumita; Sengupta, Sayoni; Dey, Debkanya; Banerjee, Rajat.

Afiliação

Bhattacharyya P; Consultant, Institute of Pulmocare and Research, Kolkata, West Bengal, India.
Saha D; Research Fellow, Institute of Pulmocare and Research, Kolkata, West Bengal, India.
Chatterjee M; Assistant Professor, Statistics, Alia University, Kolkata, West Bengal, India.
Sengupta S; Research Fellow, Institute of Pulmocare and Research, Kolkata, West Bengal, India.
Dey D; Research Fellow, Institute of Pulmocare and Research, Kolkata, West Bengal, India.
Banerjee R; Department of Biotechnology and Dr. B. C. Guha Centre for Genetic Engineering and Biotechnology, University of Calcutta, Kolkata, West Bengal, India.

Lung India ; 40(3): 227-234, 2023.

Article em En | MEDLINE | ID: mdl-37148020

Palavras-chave

Antimuscarinic agents; FEV1; LAMA; SABA; bronchodilator reversibility; glycopyrronium; salbutamol

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline Idioma: En Revista: Lung India Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google